Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.67 |
| ▸ | LMNA | P02545 | 3/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | POLA1 | P09884 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.41 |
| ▸ | DGKA | P23743 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31049868 | 1.00 | TSHR (0.67) | TSHRLMNAALDH1A1L3MBTL1KMT2A | |
| SCHEMBL4006166 | 1.00 | TSHR (0.67) | TSHRLMNAALDH1A1L3MBTL1KMT2A | |
| SCHEMBL1365242 | 1.00 | TSHR (0.67) | TSHRLMNAALDH1A1L3MBTL1KMT2A | |
| SCHEMBL11849992 | 1.00 | TSHR (0.67) | TSHRLMNAALDH1A1L3MBTL1KMT2A | |
| SCHEMBL16719251 | 1.00 | TSHR (0.67) | TSHRLMNAALDH1A1L3MBTL1KMT2A | |
| SCHEMBL1115015 | 1.00 | TSHR (0.67) | TSHRLMNAALDH1A1L3MBTL1KMT2A | |
| SCHEMBL8973175 | 1.00 | TSHR (0.67) | TSHRLMNAALDH1A1L3MBTL1KMT2A | |
| SCHEMBL1285241 | 1.00 | TSHR (0.67) | TSHRLMNAALDH1A1L3MBTL1KMT2A | |
| SCHEMBL454130 | 1.00 | TSHR (0.67) | TSHRLMNAALDH1A1L3MBTL1KMT2A | |
| SCHEMBL31734806 | 1.00 | TSHR (0.67) | TSHRLMNAALDH1A1L3MBTL1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 119 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116768857-A | EZH2/HDAC double-target inhibitor and preparation method and medical application thereof | 中国药科大学 | 2023-09-19 | — | — | CN | claimed |
| US-12522612-B2 | PDE4 inhibitors, pharmaceutical compositions, and therapeutic applications | BIOTHERYX INC. (US) | 2026-01-13 | — | — | US | disclosed |
| EP-4355741-B1 | SOS1 PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | BIOTHERYX INC (US) | 2025-12-10 | — | — | EP | disclosed |
| WO-2025224102-A1 | HDAC6 PROTACS AND THEIR USE IN THE TREATMENT OF CANCER, NEURODEGENERATIVE DISEASES, INFLAMMATION AND METABOLIC DISORDERS | THE ROYAL COLLEGE OF SURGEONS IN IRELAND (IE) | 2025-10-30 | — | — | WO | disclosed |
| WO-2025104695-A1 | IONIZABLE CATIONIC LIPIDS AND LIPID NANOPARTICLES THEREOF | Corti Therapeutics Pte. Ltd. (SG) | 2025-05-22 | — | — | WO | disclosed |
| CN-118725012-A | Compound capable of inducing KRAS protein degradation and preparation method and application thereof | 中国科学院上海药物研究所 | 2024-10-01 | — | — | CN | disclosed |
| US-20240174643-A1 | SOS1 PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | BIOTHERYX, INC. (US) | 2024-05-30 | — | — | US | disclosed |
| CN-118063489-A | Evodiamine compound and pharmaceutical application thereof | 中国医学科学院药物研究所 | 2024-05-24 | — | — | CN | disclosed |
| CN-117624134-B | Compound for targeted degradation of HDAC4, and preparation method and application thereof | 南昌市第一医院 | 2024-05-03 | — | — | CN | disclosed |
| EP-4355741-A1 | SOS1 PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | Biotheryx, Inc. (US) | 2024-04-24 | — | — | EP | disclosed |
| US-4853386-A | INHIBITORS OF SRS-A(SLOW REACTING SUBSTANCE OF ANAPHYLAXIS) FROM LUNG TISSUES | BOEHRINGER MANNHEIM GMBH (DE) | 1989-08-01 | — | — | US | disclosed |
| EP-0051829-B1 | N-SUBSTITUTED OMEGA-(2-OXO-4-IMIDAZOLIN-1-YL) ALCANOIC ACIDS, SALTS AND ESTERS THEREOF, PROCESS FOR PRODUCING THE SAME AND THESE ACTIVE AGENTS CONTAINING PHARMACEUTICAL COMPOUNDS | A. Nattermann & Cie. GmbH (DE) | 1984-12-05 | — | — | EP | disclosed |
| EP-0051828-B1 | N-BENZOYL-ALPHA-ANILINO ALKANE CARBOXYLIC ACIDS, SALTS AND ESTERS THEREOF, PROCESS FOR PRODUCING THE SAME AND PHARMACEUTICAL PREPARATIONS CONTAINING THE SAME | A. Nattermann & Cie. GmbH (DE) | 1984-03-14 | — | — | EP | disclosed |
| US-4386031-A | ANTICOAGULANTS; ANTIALLERGENS; ANTINFLAM-MATORY AND ANTILIPEMIC AGENTS; ANTIHISTAMINES; CARDIOVASCULAR DISORDERS | A. NATTERMANN & CIE GMBH (DE) | 1983-05-31 | — | — | US | disclosed |
| US-4349684-A | ANTIALLERGENS, ANTIASTHMATICS | A. NATTERMANN & CIE GMBH (DE) | 1982-09-14 | — | — | US | disclosed |
| EP-0051829-A1 | N-substituted omega-(2-oxo-4-imidazolin-1-yl) alcanoic acids, salts and esters thereof, process for producing the same and these active agents containing pharmaceutical compounds | A. Nattermann & Cie. GmbH (DE) | 1982-05-19 | — | — | EP | disclosed |
| EP-0051828-A1 | N-benzoyl-alpha-anilino alkane carboxylic acids, salts and esters thereof, process for producing the same and pharmaceutical preparations containing the same | A. Nattermann & Cie. GmbH (DE) | 1982-05-19 | — | — | EP | disclosed |
| US-3993773-A | Control of mites with esters of cyclopropane substituted carboxylic acids | ZOECON CORPORATION (US) | 1976-11-23 | — | — | US | disclosed |
| US-3969384-A | Esters of cyclopropane alkanoic acids | ZOECON CORPORATION (US) | 1976-07-13 | — | — | US | disclosed |
| US-3960907-A | MITICIDES | ZOECON CORPORATION (US) | 1976-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240174643-A1 | SOS1 PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | SOS1, SOS2, SOST | TSHR 2564/4885LMNA 3406/4885ALDH1A1 3542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.